887 results on '"Lahuerta, Juan-José"'
Search Results
2. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
3. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma
4. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma
5. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma
6. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
7. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
8. A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis
9. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
10. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma
11. Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma
12. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
13. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
14. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
15. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
16. Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
17. Signs of prehistory in the artistic economy of l’Esprit Nouveau
18. AL Amyloidosis and Multiple Myeloma: A Complex Scenario in Which Cardiac Involvement Remains the Key Prognostic Factor
19. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure
20. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
21. Measurable residual disease in multiple myeloma: ready for clinical practice?
22. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
23. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
24. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma
25. Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role
26. Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry
27. A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
28. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
29. Supplementary Figure from A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
30. Figure S1 from Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission
31. Table S2 from Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission
32. Supplementary Data from A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
33. Online Supplement from Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission
34. Bioavailability of Bioactive Compounds from Reconstituted Grapefruit Juice as Affected by the Obtention Process
35. Cell Count Differentials by Cytomorphology and Next-Generation Flow Cytometry in Bone Marrow Aspirate: An Evidence-Based Approach
36. Composition of Powdered Freeze-Dried Orange Juice Co-Product as Related to Glucose Absorption In Vitro
37. Cell Count Differentials by Cytomorphology and Next-Generation Flow Cytometry in Bone Marrow Aspirate: An Evidence-Based Approach
38. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
39. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
40. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
41. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial
42. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
43. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance
44. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis
45. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM
46. Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
47. Treatment for patients with newly diagnosed multiple myeloma in 2015
48. Conversación con Juan José Lahuerta, en torno al estudiante de arquitectura Antoni Gaudí
49. Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM)
50. Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.